Specialist Updates 
Cardiology

Combo therapy lowers natriuretic peptide, study shows

But the study, PARALLAX, found no benefit in a six-minute walk test, researchers say
Medicom Staff writer
0
3 September 2020
Save
Please login to bookmark Close

AusDoc brings you the latest news from the European Society of Cardiology Congress 2020.

Results of a trial of sacubitril and valsartan in patients with heart failure with preserved ejection fraction (HFpEF) show a reduction in N-terminal pro-b-type natriuretic peptide ( NT-proBNP), researchers report.

In the PARALLAX study, reported at the European Society of Cardiology’s virtual congress (ESC 2020) this week, patients with HFpEF were randomised to titrated dosing of sacubitril/valsartan or individualised care.

The individualised care aimed to continue their current therapy drug class: either the angiotensin receptor blocker, valsartan, the ACE-inhibitor, enalapril, or placebo, for patients not on a renin angiotensin system inhibitor, with titrated dosing.

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .